TOPIC HIGHLIGHT

WJG 20th Anniversary Special Issues (1): Hepatocellular carcinoma

Current management of hepatocellular carcinoma

Parissa Tabrizian, Sasan Roayaie, Myron E Schwartz

Parissa Tabrizian, Sasan Roayaie, Myron E Schwartz, Mount Sinai Liver Cancer Program, Mount Sinai Medical Center, New York, NY 10029, United States
Author contributions: Tabrizian P, Roayaie S and Schwartz ME contributed equally to the conception and design of data; Tabrizian P and Schwartz ME acquisition of data, drafting, and final approval of the article.
Correspondence to: Myron E Schwartz, MD, FACS, Mount Sinai Liver Cancer Program, Mount Sinai Medical Center, 1 Gustave Levy Place, Box 1104, New York, NY 10029, United States. myron.schwartz@mountsinai.org
Telephone: +1-212-6598084 Fax: +1-212-2412138
Received: January 9, 2014   Revised: May 8, 2014
Accepted: May 25, 2014
Published online: August 14, 2014

Abstract

Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and leading cause of death among patients with cirrhosis. Treatment guidelines are based according to the Barcelona Clinic Liver Cancer staging system. The choice among therapeutic options that include liver resection, liver transplantation, locoregional, and systemic treatments must be individualized for each patient. The aim of this paper is to review the outcomes that can be achieved in the treatment of HCC with the heterogeneous therapeutic options currently available in clinical practice.

Core tip: Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and its incidence is rising in Western countries. The choice among therapeutic options that include liver resection, liver transplantation, locoregional, and systemic treatments must be individualized for each patient. The aim of this paper is to review the outcomes that can be achieved in the treatment of HCC with the heterogeneous therapeutic options currently available in clinical practice.

INTRODUCTION

Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and the third most frequent cause of cancer-related death[1]. With increasing incidence in Western countries, HCC remains the leading cause of death among patients with cirrhosis[2,3]. The implementation of surveillance programs has allowed early tumor diagnosis, resulting in increased curative treatments achieving 5 year survival rates up to 75%[4,5]. The choice among therapeutic options that include liver resection, liver transplantation, locoregional, and systemic treatments must be individualized for each patient. The majority of trials now choose the Barcelona Clinic Liver Cancer (BCLC) staging system to guide treatment decisions[6-8]. Despite improved outcomes, recurrence after curative treatments remains a significant problem and is reported as high as 70% at 5 years after resection; the optimal treatment of recurrent HCC remains unclear[4]. The aim of this paper is to review the outcomes that can be achieved in the treatment of HCC with the heterogeneous therapeutic options currently available in clinical practice.

STAGING SYSTEMS AND GUIDELINES

In the past, the diagnosis of HCC was usually made at an advanced stage with patients presenting with symptom-

Figure 1 Barcelona Clinic Liver Cancer staging system and treatment strategy (2011). HCC: Hepatocellular carcinoma; CLT: Cadaveric liver tansplantation; LDLT: Living donor transplantation; RF: Radiofrequency; PEI: Percutaneous ethanol injection; TACE: Transarterial chemoembolization; PST: Performance status test.

atic disease and liver impairment[6,9]. Treatment was futile with median survival rates of less than 3 mo[6,9]. In addition, morbidity associated with therapy was significantly high[10,11]. Recent advances in technology and surveillance programs have led to more frequent early HCC diagnosis offering curative treatments with 5 year survival rates ranging from 50% to 75%[4,5].

Among the many HCC staging systems that have been developed around the world, the BCLC staging system has emerged as the most useful to guide treatment decisions (Figure 1). The BCLC staging was first developed based on analysis of independent studies of the various treatment modalities applied in various clinical settings. It includes variables related to tumor stage, liver functional status, performance status, and cancer-related systems, its key feature being evidence-based linkage of clinical stage with treatment modalities, allowing an estimation of life expectancy based on published results. BCLC identifies patients with early HCC who are potentially curable, those at intermediate or advanced disease stage for whom noncurative treatment offers the likelihood of extended survival, and those at end stage for whom treatment would provide more harm than benefit.

Ongoing molecular studies are rapidly shedding light on the heterogeneous underlying mechanisms that drive the development and progression of HCC and offer promise of therapies that target the specific abnormalities that lead to and sustain the growth of HCC in individual patients[12-14].

OVERVIEW OF TREATMENT OPTIONS FOR HCC

Given the complexity of the disease and the large num-

ber of useful therapies, patients with HCC should be cared for by multidisciplinary teams. It is important to note that the level of evidence for most of the therapeutic options is limited to cohort investigations with few RCTs, most of which are limited to the treatment of advanced disease; as with most cancers, surgical treatment for early stage disease has not been compared to no treatment in prospective trials[15,16].

Table 1 summarizes existing series and the level of evidence for efficacy according to trial design and endpoints for all available treatments in HCC[4,5,17-31]. Availability of resources also has to be considered in developing treatment strategies. This is particularly relevant when considering liver transplantation, which is unavailable in some areas of the world.

Resection

Selection criteria: Hepatic resection is widely accepted as first-line treatment for patients with early-stage HCC and preserved liver function[4,32]. The choice of treatment modality in cirrhotic patients (who comprise the majority HCC cases) is challenging and requires assessment of both liver function reserve and tumor extension. Child-Pugh class is commonly used as a basis for estimating hepatic reserve, with resection confined to patients who are Child-Pugh class A; in Asia indocyanine green retention rate at 15 min (ICG 15) is often used as a direct measure of liver function[33,34]. Portal hypertension as assessed by platelet count or direct measurement of hepatic venous pressure gradient has been recognized as a major prognostic factor in the treatment of HCC[35,36]. The BCLC group showed 70% 5-year survival for patients without portal hypertension and with bilirubin < 1 compared with 50% in patients with both risk factors present[4].

Table 1 Existing series on treatment of hepatocellular cancer: evidence based benefit (NCI classification) and outcome

Treatment	Ref.	Year	Number	5 yr survival
Liver resection (evidence 2A)	Llovet et al[4]	1999	77	51%
	[1]Fong et al[5]	1999	154	57%
	[2]Roayaie et al[17]	2012	132	70%
Liver transplantation (evidence 2A)	Mazzaferro et al[18]	1996	444	73.3%
	Llovet et al[4]	1999	87	69%
	Yao et al[19]	2001	70	72.4%
	[3]Roayaie et al[20]	2002	43	44%
	[4]Mazzaferro et al[21]	2009	48	75%
Radiofrequency ablation (evidence 2A)	[2]Sala et al[22]	2004	34	63%
	Vivarelli et al[23]	2004	79	33% (3 yr)
	[1]Chen et al[24]	2006	71	67.9% (4 yr)
Transarterial chemoembolization (evidence 1A)	DETCH[25]	1995	50	38% (2 yr)
	Llovet et al[26]	2002	40	29% (3 yr)
	Lo et al[27]	2002	40	31% (2 yr)
Radiotherapy (evidence 1A)	[5]Carr[28]	2004	65	Median 21.3 mo
	[6]Salem et al[29]	2011	123	Median 20.7 mo
Systemic therapy (evidence 1A)	Llovet et al[30]	2008	299	10.7 mo
	Cheng et al[31]	2009	150	6.5 mo

[1]< 5 cm HCC; [2]< 3 cm HCC; [3]> 5 cm HCC; [4]Within Milan criteria; [5]Stage I disease; [6]Child-Pugh A. DETCH: Group d'Etude et de Traitement du Carcinome Hépatocellulaire; HCC: Hepatocellular carcinoma.

Preoperative portal vein embolization (PVE) is often employed to induce growth of the remnant liver prior to major resection, typically right hepatectomy[11,37,38]. The regenerative response to PVE in cirrhosis is less-reliable and takes longer than with normal parenchyma; indeed, response to PVE may be considered a "stress test" for the liver. While anatomic resection is of proven benefit in HCC, it is preferable to perform limited anatomic resection, *i.e.*, segmentectomy or sectorectomy, when possible and to avoid right hepatectomy in cirrhotic patients[39].

The main prognostic predictors after liver function status are tumor size, number of tumors, presence of satellite lesions, and vascular invasion[4,40-42]. These factors should be carefully assessed by contrast-enhanced computed tomography and/or magnetic resonance imaging. Intraoperative ultrasonography is routine in resection of HCC, enabling detection of additional small nodules and defining the relationship of the tumor to intrahepatic structures.

Perioperative outcome: The perioperative mortality of major resection has decreased in the past few decades from 15% in the 1980s to 3%-5% in the majority of large referral centers, with some centers reporting < 1% mortality[10,11,32]. Predictors of perioperative mortality are primarily related to liver function and include Child-Pugh class, degree of hepatic fibrosis, total bilirubin level, presence of clinically relevant portal hypertension, and platelet count.

High operative blood loss and transfusions have repeatedly been shown to correlate with poor outcome; refinement of patient selection as well as of surgical technique has led to improvement in this regard. Inflow occlusion (Pringle maneuver) is widely applied, and many studies have compared different occlusion methods[43,44]. Intermittent inflow occlusion has been shown to decrease

ischemia/reperfusion injury with subsequently reduced morbidity and mortality rates, and is the procedure of choice at most centers. Total hepatic vascular exclusion has a role in resection of tumors that are adjacent to the vena cava and/or large hepatic veins, but is rarely applied in cirrhotic patients. In all cases, maintenance of low central venous pressure (< 5 mmHg) by the anesthesiologist is the best way to limit bleeding from hepatic veins during the division of the liver[11].

There is an array of techniques and technologies available for dividing liver parenchyma[45]. Since no one method is suitable for all situations, it is important to master a few techniques and to have a flexible approach.

These combined strategies, in addition to improved perioperative management, have led to a decrease in blood transfusion from 80% to 90% to less than 10% over the past two decades[11].

Recurrence and survival: Recurrence after resection is common; even with early-stage HCC recurrence develops in approximately 20%, 50% and 75% of patients at 1 year, 3 years and 5 years, respectively[4,16,32]. Recurrence of HCC may be the result either of metastasis from the primary tumor that was resected (true recurrence), or *de novo* HCC due to the underlying predisposition; while molecular testing is required to definitively distinguish between the two, most true recurrence manifests within 2 years of resection, and thus 2 years is often adopted as a practical cut-off to distinguish between true recurrence and de novo HCC[7,42]. Predictors of true recurrence include tumor grade, microscopic and macroscopic vascular invasion, tumor size, number of tumors, presence of satellites, alpha-fetoprotein level, transfusion, and positive surgical margin[4,40-42]. Postresection survival rates are in the range of 80%-92% at 1 year, 61%-86% at 3 years, and 41%-74% at 5 years (Table 2)[4,5,17,46-49]. The nature of

Table 2 Outcome of patients with hepatocellular carcinoma treated by resection, liver transplantation, and living donor liver transplantation

Treatment	No. of patients	1 yr survival	5 yr survival
Surgical resection			
Fong *et al*[5] 1999	154	81%	37%
Llovet *et al*[4] 1999	77[1]	85%	51%
Poon *et al*[46] 2002	135[2]	90%	70%
Wayne *et al*[47] 2002	249 (≤ 5 cm)	83%	41%
Shrager *et al*[48] 2012	206[1]	60%	46%
Roayaie *et al*[17] 2013	132 (≤ 2 cm)	-	70%
Liver transplantation			
Mazzaferro *et al*[18] 1996	48	84%	74%
Bismuth *et al*[82] 1999	45	82%	74%
Llovet *et al*[4] 1999	79	86%	75%
Jonas *et al*[83] 2001	120	90%	71%
Yao *et al*[19] 2001	64	87%	73%
Living donor transplantation			
Gondolesi *et al*[84] 2004	15	-	86% (3 yr)
Todo *et al*[85] 2004	137	-	79% (3 yr)

[1]Cirrhosis; [2]Child A cirrhosis and small lesion HCC. HCC: Hepatocellular carcinoma.

Table 3 Independent predictors of recurrence and survival in patients undergoing resection for hepatocellular carcinoma

Ref.	No. of patients	Variables
Belghiti *et al*[50] 1991	47	Tumor size ≥ 5 cm
		AFP levels ≥ 100 ng/mL
Llovet *et al*[4] 1999	77	Differentiation degree
		Multinodularity
		Satellites
Imamura *et al*[42] 2003	184	Early recurrence (< 2 yr)
		Microvascular invasion
		AFP levels ≥ 32 ng/mL
		Non-anatomical resection
		Late recurrence (> 2 yr)
		Higher grade of hepatitis activity
		Multinodularity
		Gross tumor classification
Roayaie *et al*[41] 2009	131	Invasion of a vessel with a muscular wall
		Tumor size > 10 cm
Survival		
Llovet *et al*[4] 1999	77	Portal hypertenstion
		Bilirubin level (> 1 mg/dL)
Wayne *et al*[47] 2002	249	Child-Pugh (B)
		Differentiation degree (Edmonson-Steiner 1-2 *vs* 3-4)
		Fibrosis (Ishak score 0-4 *vs* 5-6)
Vauthey *et al*[51] 2002	557	Vascular invasion
		Multinodularity
		Tumor size (> 5 cm)
		Fibrosis
Poon *et al*[52] 2003	518	Vascular invasion
		Tumor size (> 5 cm)
		Multinodularity
		Cirrhosis
		AST > 50 U/L
		Invasion of adjacent organs
Roayaie *et al*[41] 2009	131	Invasion of a vessel with a muscular wall
		Invasion > 1 cm from tumor

AFP: Alpha-fetoprotein.

the underlying liver disease is important: patient survival is higher and HCC recurrence is less-common in patients with hepatitis B compared to those with hepatitis C[42]. The independent predictors of recurrence and survival are summarized in Table 3[4,41,42,47,50-52].

Adjuvant therapies to prevent recurrence: The only adjuvant therapy of proven value is treatment of underlying viral hepatitis. Remarkable advances have been made in the past decade in preventing recurrent HCC with the use of antiviral treatment, either after local resection or locoregional tumor ablation. Antiviral therapy of hepatitis B, especially with nucleoside analogues, has been shown to reduce *de novo* HCC recurrence as well as to retard progression of cirrhosis[16,53,54]. Similarly, interferon-based therapy has been shown to reduce de novo HCC in patients who comply with the treatment regimen[55,56]. Several RCT have been conducted to explore strategies to prevent true recurrence (Table 4)[57-64]. Chemoembolization, systemic chemotherapy, and interferon did not provide benefit[59,65]. Intraarterial radiotherapy with iodine-131 (^{131}I) iodized oil showed improved outcome in two small RCT's but is currently unavailable[66,67]. Decreased HCC recurrence was reported with acyclic retinoids in 1996, but a follow-up study has proven negative[68]. Samuel *et al*[69] published a review of 12 RCTs and demonstrated no clear evidence for the efficacy of any of the adjuvant or neoadjuvant protocol. The result of a large randomized trial evaluating sorafenib in the adjuvant setting is currently underway[70].

Treatment of recurrent HCC after resection: In 65%-80% of cases of recurrent HCC the liver is the sole site of disease[42]. Repeat resection has been widely accepted as the treatment of choice for recurrent intrahepatic

HCC in patients with well preserved liver function and solitary tumors[71]. Applicability of repeat hepatectomy in published series ranges from 10% to 35%, with 5-year survival reported from 37%-87%[71,72]. Roayaie *et al*[71] identified time from primary resection to recurrence (< 1 year) and presence of gross vascular invasion at second hepatectomy as predictors of poor outcome in patients undergoing repeat hepatectomy, providing some guidance in case selection.

OLT may be applied secondarily to treat recurrent HCC after hepatectomy and several authors have explored the possibilities of "salvage" transplantation[73-75]. Cherqui *et al*[76] found that 61% of patients with recurrent HCC after resection had recurrence within transplant eligibility criteria, and that 5-year survival after retransplant was 70%.

Transcatheter chemoembolization (TACE) is the most widely used treatment modality for recurrent intrahepatic HCC in patients with unresectable disease. Several retrospective studies have reported 1-year survival of 64%-88% with 5-year survival ranging from 0%-27%[77,78].

Table 4 Result of randomized controlled trials: Adjuvant/neoadjuvant treatment in resected hepatocellular cancer

Ref.	Treatment	Recurrence rate-3 yr
Izumi *et al*[57] 1994	Adjuvant arterial lipiodolization (23) *vs* control (27)	No differences
Lai *et al*[58] 1998	Adjuvant chemoembolization (30) *vs* control (36)	82% *vs* 52%, *P* = NS
Yamasaki *et al*[59] 1996	Neoadjuvant chemoembolization (50) *vs* control (47)	54% *vs* 66%, *P* = NS
Lau *et al*[60] 1999	Adjuvant intraarterial lipiodol [131]I (21) *vs* control (22)	75% *vs* 38%, *P* = 0.03
Lygidakis *et al*[61] 1996	Adjuvant chemoembolization + immunotherapy (49) *vs* control (42)	36 mo *vs* 18 mo (OS)
Takayama *et al*[62] 2000	Adjuvant immunotherapy (76) *vs* control (74)	33% *vs* 48%, *P* = 0.008
Yamamoto *et al*[63] 1996	Adjuvant 5-FU (35) *vs* control (32)	52% *vs* 75%, *P* = NS
Kubo *et al*[64] 2001	Adjuvant Interferon alpha (15) *vs* control (15)	30% *vs* 60%, *P*= 0.03

NS: Not significant; OS: Overall survival; FU: Fluorouracil.

Table 5 Selection criteria for transplantation in hepatocellular carcinoma

Ref.	No. of patients	Selection criteria	Survival rate at 5 yr
Mazzaferro *et al*[18] 1996	48	Milan criteria: single HCC < 5 cm or up to 3 nodules < 3 cm	75% (4 yr)
Yao *et al*[19] 2001	70	UCSF criteria: a maximum tumor size of 6.5 cm or 2 lesions ≤ 4.5 cm in diameter with a total tumor diameter of ≤ 8 m	75%
Kwon *et al*[86] 2007	114	HCC ≤ 5 cm AFP ≤ 400 ng/mL	87%
Lee *et al*[87] 2008	186	Up to 6 nodules with a maximum diameter of < 5 cm	76%
Mazzaferro *et al*[21] 2009	283	Up to 7 criteria: 7 as the sum of the largest size (cm) and the number of tumors	71%
Herrero *et al*[88] 2001	154	HCC ≤ 6 cm or ≤ 3 HCC ≤ 5 cm	73%
Jonas *et al*[89] 2007	21	Any number, each ≤ 6 cm with cumulated diameter ≤ 15 cm	62% at 3 yr
Toso *et al*[90] 2008	288	TTV ≤ 115 cm^3	72%
Sugawara *et al*[91] 2007	78	≤ 5 HCC ≤ 5 cm	70% at 3 yr

TTV: Total tumor volume; HCC: Hepatocellular carcinoma; AFP: Alpha-fetoprotein; UCSF: University of California, San Francisco.

These results are not dissimilar to those reported in primary BCLC B HCC.

There are few data available on the management of extrahepatic recurrence after hepatectomy, all from small case series. Independent predictors of survival after recurrence include time from primary resection to recurrence > *vs* < 1 year, size and number of recurrent tumor nodules, site of recurrence, alpha-fetoprotein (AFP) level at recurrence, and type of treatment[77-80]. These studies suggest that aggressive surgical treatment may be of benefit in patients with isolated metastasis, with the most common site being the lung: Lam *et al*[81] reported 67% 5-year survival after resection of solitary lung metastasis.

Transplantation

Selection criteria: Orthotopic liver transplantation (OLT) is an appealing option for cirrhotic patients with early stage HCC, since it allows removal of both detectable and undetectable HCC in the liver and also treats the underlying cirrhosis. OLT is, however, limited by graft shortage, and appropriate patient selection is critical to achieving satisfactory results[4,18]. The outcomes have improved in the past decades with 5-year survival rates from 18%-40% in the 1980s rising to 85% 1-year and 70% 5-year survival in recent reports (Table 2)[4,18,19,82-85]. In a landmark study, Mazzaferro *et al*[18] proposed a strict criteria for OLT that result in survival rates equal to those in cirrhotic patients without HCC, with 5 year overall and recurrence free sur-

vival of 75% and 83% respectively. The "Milan Criteria" (solitary tumor ≤ 5 cm, or 2-3 nodules all < 3 cm and without gross vascular invasion or extrahepatic spread) are now widely accepted as the basis for selecting candidates with HCC for transplantation and have been adopted in the United States by United Network for Organ Sharing (UNOS) as the basis for prioritizing HCC patients for OLT[18]. Consensus guidelines suggest that OLT is the treatment choice for patients with Child's B cirrhosis and/or portal hypertension and HCC within Milan criteria; hepatectomy remains the accepted first-line treatment for patients with preserved liver function and early-stage HCC.

Based on the success of OLT for HCC within Milan criteria, controversy has arisen over expansion of the Milan criteria (Table 5)[18,19,21,86-91]. The most widely-recognized study (UCSF criteria) was proposed by Yao and colleagues as the UCSF criteria (single nodule < 6.5 cm, or ≤ 3 nodules the largest of which is ≤ 4.5 cm with the cumulative tumor diameters ≤ 8 cm)[19]. Small studies evaluating post-OLT survival rates in patients who meet the UCSF but exceed the Milan criteria have shown 5-year survival ranging from 38%-93%[92,93]. Although there is no question that many patients would be cured with the adoption of broader criteria, opponents challenge the expansion due to concern that it will lead to increased risk of vascular invasion and tumor recurrence that they consider unacceptable in light of the widespread donor

Table 6 Independent predictors of recurrence and survival in patients undergoing liver transplantation for hepatocellular carcinoma

Ref.	No. of patients	Variables
Recurrence		
Iwatsuki et al[108] 2000	344	Bilobar disease
		Vascular invasion
		Tumor size (2-5 cm, > 5 cm)
Bismuth et al[109] 1993	60	Tumor size
		Number of tumors
		Portal thrombus
Roayaie et al[110] 2000	119	Tumor size
		Vascular invasion
Hemming et al[111] 2002	112	Vascular invasion
Survival		
Iwatsuki et al[108] 2000	344	Number of tumors (> 3)
		Vascular invasion
Jonas et al[83] 2001	120	Vascular invasion
		Tumor grade

organ shortage[92].

Drop-out rates and downstaging: For patients without HCC, prioritization for OLT is based on the Model for End Stage Liver Disease (MELD) score[94]. The MELD score, which ranges from 6 to 40 and is calculated based on total bilirubin, creatinine, and prothrombin time international normalized ratio (INR), provides an objective and reliable index of 3-mo mortality in cirrhotic patients[94]. For patients with HCC, however, the primary risk is not death due to liver failure but rather progression of HCC to the point where transplant is no longer worthwhile. Current UNOS policy accords patients with T2 HCC (single nodule between 2-5 cm or 2-3 nodules all < 3 cm) an initial score of 22 points ("MELD exception") that rises every three months as long as the tumor is maintained within Milan criteria[95]. This has resulted in both increased transplant rates and excellent long-term outcomes[94].

Despite this policy, however, in many regions of the US patients must wait a year or more for a donor liver. As a result, drop-out from the waiting list due to tumor progression is an important problem that can significantly decrease the survival of transplant for HCC when viewed on an intention-to-treat basis[4]. Identified risk for drop-out include multinodular tumors, failed neoadjuvant therapy, baseline AFP > 200 ng/mL, or steady increase of > 15 ng/mL per month[96]. Numerous studies have examined the role of locoregional therapies as a "bridge" to OLT in order to prevent tumor progression and drop-out and possibly to improve posttransplant outcomes, but none are of adequate design or sufficient power to provide strong evidence in support of this approach[7,97]. Thermal ablation techniques are typically employed to treat solitary nodules > 3 cm, while TACE is commonly preferred for larger or multinodular tumors[98,99]. Based on the available evidence, guidelines recommend locoregional treatment of HCC in patients awaiting OLT when the estimated waiting time will exceed 6 mo.

In an attempt to better define a subset of patients with HCC beyond Milan criteria who could benefit from OLT, a number of reports have explored the concept of downstaging, *i.e.*, nonsurgical tumor treatment to reduce the size and/or number of viable lesions to within acceptable criteria, typically the Milan criteria[99,100]. The rationale of downstaging per se is dubious; all reported protocols include a minimum waiting period after locoregional therapy, typically 3-6 mo, to allow for assessment of tumor behavior. Several single-center studies have reported excellent results with patient survival and the incidence of HCC recurrence comparable those achieved in patients initially within Milan criteria; to this point the evidence is not strong enough for downstaging to have been accepted into guidelines or organ allocation policy[100-103].

Living donor transplantation (LDLT) is, for patients with a suitable and willing donor, a way to eliminate waiting time and the attendant risk of drop-out. In patients fulfilling the Milan criteria, 5-year survival after LDLT is similar to after deceased donor OLT (Table 2), though there is a suggestion of a higher rate of HCC recurrence[84,85,104,105]. Because there is no competition for living donor organs, many centers also offer this option to patients with HCC that is modestly beyond Milan criteria, with reported 5 year survival rates up to 60%[106,107].

Recurrence and outcome: Post-OLT HCC recurrence is seen in 10%-15% of patients transplanted within the Milan criteria[4,18]. It is the result of extrahepatic dissemination of HCC that has occurred before or during the transplant procedure, although interestingly intrahepatic recurrence is common site. The large majority of recurrences are within 2 years of OLT[4,18]. Reported predictors of post-OLT HCC recurrence are summarized in Table 6, foremost among them being the finding of vascular invasion on examination of the explanted liver[83,108-112].

Overall post-OLT 5-year survival for patients with HCC within Milan criteria is in the range of 70%-75%, though results in patients with associated hepatitis C are around 10% lower than in patients with other underlying diseases[4,18,113]. When considering OLT as an alternative to resection in patients eligible for both, it becomes important to view OLT on an intention-to-treat basis, incorporating waiting list drop-out. When waiting time is > 6 mo, 5-year intention-to-treat survival has been shown to be reduced by 10%-20% (from 58%-81% to 47%-62%)[114].

Post-OLT survival in patients who develop HCC recurrence is approximately 22% at 5 years[115]. Independent predictors of poor survival from the time of recurrence include tumor grade (poor), time to recurrence < 1 year, and presence of bone metastasis[115]. Patients who undergo locoregional or surgical treatment for recurrent HCC enjoy significantly better outcomes than other patients, but it is difficult to fully account for case selection bias in the available retrospective reports. Isolated hepatic recurrence, observed in 15%-20% of cases, is the pattern

Table 7 Randomized controlled trial comparing radiofrequency ablation to percutaneous ethanol injection for the treatment of early stage hepatocellular carcinoma

Ref.		No. of patients	Initial response	Failure	3 yr survival	P value
Lencioni *et al*[128]	RFA (52)		91%	8%	81%	NS
2003	PEI (50)		82%	34%	73%	
Lin *et al*[129]	RFA (52)		96%	17%	74%	0.014
2004			88%			
	PEI (52)		88%	45%	50%	
Shiina *et al*[122]	RFA (118)		100%	2%	80%	0.020
2005	PEI (114)		100%	11%	63%	
Lin *et al*[130]	RFA (62)		97%	16%	74%	0.031
2005	PEI (62)		89%	42%	51%	
Brunello *et al*[131]	RFA (70)		96%	34%	59%	NS
2008	PEI (69)		66%	64%	57%	

RFA: Radiofrequency ablation; PEI: Percutaneous ethanol injection; NS: Not significant.

most amenable to locoregional therapy[116]. Hepatic resection for isolated recurrent disease post-OLT can achieve 5-year survival up to 66%[115-117]. Response to TACE for treatment of recurrent HCC has been demonstrated to be similar to that observed in primary HCC[116,118]. A few Asian reports describe retransplantation for post-OLT HCC recurrence, but there is a broad consensus against this approach[119,120].

Ablation

Thermal (RFA, microwave) or chemical (ethanol, acetic acid) is the treatment of choice in patients with single small tumors who are not candidates for surgery, and may be curative in well-selected candidates[16,114].

Percutaneous ethanol injection (PEI) is a long-established technique for the treatment of nodular-type HCC, inducing coagulation necrosis of the lesion as a result of cellular dehydration, protein denaturation, and chemical occlusion of small tumor vessels[121]. For tumors < 2 cm, PEI has been shown to yield equivalent results to thermal ablation; for larger tumors PEI is inferior to thermal ablation and is now rarely performed[122].

Thermal ablation has now largely supplanted PEI, initially with RFA and more recently with microwave ablation[121,123]. While most commonly performed percutaneously, ablation can also be done *via* an open or laparoscopic surgical approach. The thermal damage caused by heating is dependent on both the tissue temperature achieved and the duration of heating. In order to achieve adequate tumor destruction, the entire lesion must be exposed to cytotoxic temperatures; in order to assure this, a rim of nontumor tissue surrounding the lesion being treated is included in the ablation zone. Thermal ablation is associated with low major morbidity (2.2%-3.1%) and mortality (0.1%-0.5%) rates[124,125]. Major complications include intraperitoneal hemorrhage, hepatic abscess, bile duct injury, and liver decompensation. Tumor seeding along the needle track has been reported as a rare (0.5%) late complication of RFA[126].

The efficacy of RFA is reduced with increasing tumor size and the presence of large (3 mm or more) abutting vessels. Complete tumor necrosis in explanted liver specimens was shown in 83% of lesions > 3 cm and in 88% of tumors in nonperivascular locations[16,125,127]. Five RCTs and a meta-analysis have confirmed the superiority of RFA over PEI except in very small lesions (Table 7)[122,128-131].

A number of studies have reported on long-term outcomes of RFA in the treatment of HCC. Lencioni *et al*[125,132] have demonstrated 61% 5-year survival in patients with Child A cirrhosis and solitary HCC, compared with 51% in patients with Child A cirrhosis and multiple tumors and 31% in patients with Child B cirrhosis.

The role of thermal ablation *vis-à-vis* resection has been the subject of a number of randomized trials. Chen *et al*[24]. demonstrated no difference in overall or recurrence-free survival in patients with solitary HCC < 5 cm Huang *et al*[133], on the other hand, showed a significant survival benefit for surgical resection (75.6% 5-year OS, 28.7% RFS) over RFA (54.8% 5-year OS, 21.3% RFS) in patients with HCC within Milan criteria. Both of these studies have been criticized due to insufficient sample size and lack of non-inferiority design[24,133]. Recently, Hasegawa *et al*[134] published data from a large Japanese cohort study and concluded that resection was associated with higher overall survival and lower recurrence rate than RFA or PEI in the treatment of HCC ≤ 3 cm. Livraghi *et al*[135] has reported complete tumor response in 97% of tumors ≤ 2 cm, with 5-year survival in patients with preserved hepatic function of 68%, in the process challenging resection as the first-line approach in such cases. Roayaie *et al*[17] reported the outcomes of resection at two large Western centers in patients for HCC ≤ 2 cm and showed a substantial incidence of vascular invasion, with anatomic resection resulting in significantly less recurrence than nonanatomic resection. The best results of resection, with 5-year survival of 81%, were achieved when the platelet count was > 150000.

Microwave ablation (MWA) is an emerging alternative method to RFA, inducing thermal injury using microwaves with a frequency of 900 kHz. Compared to RFA, MWA is less-susceptible to the heat sink effect of nearby blood vessels. In the one RCT thus far reported RFA proved superior with respect to local recurrence and complications rates, but with the rapid evolution of the technology the outcome of MWA has improved[136].

The use of other ablative technologies including laser ablation, cryoablation, and irreversible electroporation, remains under clinical investigation[16].

Chemoembolization

TACE, the image-guided delivery of embolic particles +/- chemotherapeutic agents *via* selective injection into vessels feeding tumors in order to achieve cytoreduction, is a well-established treatment for intermediate stage (BCLC stage B) HCC[16,26,137]. TACE has been shown both in RCTs and in a meta-analysis of RCT's to provide survival benefit in patients with preserved liver function

Table 8 Randomized controlled trias comparing transarterial chemoembolization or transarterial embolization to other treatments				
Ref.	No. of patients	1 yr survival	2 yr survival	*P* value
Lin *et al*[141] 1988				
TAE (gelfoam + ivalon)	21	42%	25	NS
TAE + IV 5-FU	21	20%	20	
IV 5-FU	21	13%	13	
Pelletier *et al*[142] 1990				
TACE (doxorubicin, gelfoam)	21	24%	-	NS
Conservative treatment	21	33%	-	
GETCH[25] 1995				
TACE (cisplatin, gelfoam)	50	62%	38	NS
Conservative treatment	46	43%	26	
Bruix *et al*[143] 1998				
TAE (gelfoam, coils)	40	70	49	NS
Conservative treatment	40	72	50	
Lo *et al*[27] 2002				
TACE (cisplatin, gelfoam)	40	57	31	0.002
Conservative treatment	39	32	11	
Llovet *et al*[26] 2002				
TACE (doxorubicin, gelfoam)	40	82	63	0.009
TAE (gelfoam)	37	75	50	
Conservative treatment	35	63	27	

NS: Not significant; IV: Intravenous; GETCH: Groupe d'Etude et de Traitement du Carcinome He'patocellulaire; TACE: Transarterial chemoembolization; TAE: Transarterial embolization; RCT: Randomized controlled trial; FU: Fluorouracil.

Table 9 Existing series on treatment of hepatocellular cancer: stereotactic body radiation therapy and radioembolization with yttrium-90				
Treatment	Ref.	Year	Number	Overall survival
Radiotherapy	Kwon *et al*[145]	2010	42	58.6% (3 yr)
	Andolino *et al*[146]	2011	60	67% (2 yr)
	Huang *et al*[147]	2012	36	64% (2 yr)
	Kang *et al*[148]	2012	47	68.7% (2 yr)
	Facciuto *et al*[149]	2012	117	[1]Median 32 mo
Radioembolization	Carr *et al*[28]	2004	65	Median 21.3 mo
	Sangro *et al*[150]	2006	24	Median 7 mo
	Kulik *et al*[151]	2008	108	[2]Median 15.6 mo [3]Median 4.4 mo
	Hilgard *et al*[152]	2010	108	Median 16.4 mo
	Salem *et al*[153]	2010	291	[4]Median 7.7 mo
	Salem *et al*[29]	2011	123	Median 20.7 mo

[1]Post liver transplant; [2]No portal vein thrombosis; [3]With main portal vein thrombosis; [4]Child B cirrhosis.

subject of a number of trials (Table 8)[122-124,141-143]. In a recent study, patients treated TACE using drug-eluting beads with epirubicin had a higher rate of complete necrosis (77% *vs* 27%) and a significantly decreased tumor progression rate compared to patients treated with bland embolization alone[144].

Radiation therapy and radioembolization
There is growing interest supported by a number of non-randomized studies in the use of stereotactic body radiation therapy (SBRT) to treat HCC in a variety of settings (Table 9)[145-149]. The best-defined role for SBRT is to treat isolated lesions of HCC, either as definitive therapy or neoadjavant to transplant, when the conventional modalities including TACE and thermal ablation are either not applicable or have failed to achieve tumor control.

Radioembolization *via* the hepatic artery using microspheres impregnated with yttrium-90 (Y90) has been investigated in the treatment of unresectable HCC (Table 9)[28,29,150-153]. The safety of this technique has been demonstrated in multiple studies, and as there is minimal embolic effect it may be safely applied to patients with tumoral invasion of the portal vein. The treatment protocol requires preliminary investigations to exclude significant hepatopulmonary shunting and to assure that the arterial anatomy is suitable to allow treatment of the involved liver without deposition of microspheres in the gastrointestinal tract.

Cohort and retrospective studies have evaluated the efficacy of radioembolization in the treatment of HCC[28,29,150-153]. Pathologic examination of livers removed at transplant in which HCC had been treated with Y90 has demonstrated complete response in 61% of cases. Median survival for patients with macroscopic portal invasion has been reported at 12 mo. These data are encouraging, and a number of RCT's are underway to clarify the role of Y90 treatment.

Another agent, ^{131}I iodized oil, has also been used for radioembolization. A small RCT from Hong Kong as well as a French study have shown increased survival

and HCC confined to the liver without macrovascular invasion: one RCT demonstrated 2-year survival of 63% *vs* 27% in untreated controls[26,27]. Based on this evidence, TACE has been incorporated into guidelines on HCC management.

Complications of TACE include nontarget embolization, postembolization syndrome (fever, abdominal pain, ileus), liver failure, cholecystitis, and acute portal vein thrombosis[138]. Treatment-related mortality is seen in less than 5% of cases[138]. Main portal vein thrombosis, poor liver function, and extrahepatic spread have been shown to be predictors of poor outcome and are considered contraindications for chemoembolization[139]. Due to increased risk of hepatic necrosis and abscess formation, a total bilirubin level greater than 3 mg/mL should be considered a relative contraindication to TACE unless selective embolization can be performed.

There is no universal standard technique for the performance of TACE; the choice of embolic agent, whether lipiodol is used, the choice of drugs, and the schedule (on demand *vs* at fixed intervals) all vary among centers. Most commonly, TACE is performed by injection of chemotherapy with or without lipiodol, followed by the injection of embolic particles to near stasis. More recently, the use of calibrated particles that adsorb chemotherapy when mixed with the drug prior to injection and slowly elute the drug after the procedure have been shown to result in fewer side-effects and, in high-risk cases, better results[140].

Whether the addition of the chemotherapy in TACE provides benefit over bland embolization has been the

Treatment	Acronym	Treatment	Primary outcome
First line treatment	[1]SEARCH	Erlotinib + Sorafenib *vs* Sorafenib	OS
	[1]BRISK-FL	Brivanib *vs* Sorafenib	OS
	-	Linifanib *vs* Sorafenib	OS
Second line treatment	[1]EVOLVE-1	Everolimus *vs* Placebo	OS
	[1]BRISK	Brivanib *vs* Placebo	OS
	[1]BRISK-APS	Brivanib *vs* Placebo	OS
Phase 2 trial (reported)	Toh *et al*[158] 2010	Linifanib	OS: 9.7 mo
	Hsu *et al*[159] 2010	Sorafenib + Tegafur/Uracil	OS: 7.4 mo
	Thomas *et al*[160] 2007	Erlotinib	OS: 6.25 mo
	Thomas *et al*[161] 2009	Erlotinib + Bevacizumab	OS: 15.7 mo
	Faivre *et al*[162] 2009	Sunitinib	OS: 8 mo

[1]ClinicalTrials.gov. Available at: http://www.clinicaltrials.gov/. OS: Overall survival.

after hepatic resection for HCC with postoperative adjuvant infusion of ^{131}I lipiodol into the hepatic artery of the remnant liver[60,67]. These results have yet to be replicated on a larger scale, and due to complexities in its production the agent is no longer available for clinical use.

Systemic therapy

Prior to 2007, there was no first-line systemic therapy with proven efficacy in HCC. In that year Sorafenib, an oral tyrosine kinase inhibitor that suppresses tumor proliferation and angiogenesis, was shown in a large Western placebo-controlled RCT to significantly prolong survival (from 7.9 mo to 10.7 mo) in patients with Child's A cirrhosis and advanced HCC (extrahepatic spread, macroscopic vascular invasion, or failure of locoregional treatment)[30]. These findings were confirmed in a second trial conducted in Asia[31]. Sorafenib was overall well-tolerated in both trials with the most common grade 3 drug-related side effects being diarrhea, weight loss, and hand/foot skin reactions[30,31].

Data on the efficacy and tolerability of sorafenib in patients with Child's B cirrhosis are limited as the majority of patients enrolled in trials have been Child's class A; such data as are available suggest markedly lower survival (median 3.2 mo for Child's B compared to 9.5 mo in Child's A cirrhosis)[154-157]. Furthermore, data on safety and dosing in Child's B patients are inadequate, particularly when the bilirubin level is elevated[16,155]. Systemic therapy should be administered with caution in these patients.

Encouraged by the success of sorafenib, a number of other studies have been undertaken using other targeted agents in combination with sorafenib, head-to-head against sorafenib, or as second-line after progression on or inability to tolerate sorafenib; to date, all completed studies have been negative (Table 10)[158-163]. A RCT looking at sorafenib after chemoembolization in an attempt to prolong time to progression also provided no meaningful benefit. A large RCT of sorafenib *vs* placebo as adjuvant therapy after resection or ablation is currently under-

way[70]. In view of these multiple failures in unselected populations of patients, attention is increasingly shifting to trial enrichment using molecular studies to identify subgroups of patients with identified drivers of tumor progression that may be rationally targeted with specific drugs.

REFERENCES

1   **Parkin DM**, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. *CA Cancer J Clin* 2005; **55**: 74-108 [PMID: 15761078]

2   **Ioannou GN**, Splan MF, Weiss NS, McDonald GB, Beretta L, Lee SP. Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. *Clin Gastroenterol Hepatol* 2007; **5**: 938-45, 945.e1-4 [PMID: 17509946 DOI: 10.1016/j.cgh.2007.02.039]

3   **Sangiovanni A**, Prati GM, Fasani P, Ronchi G, Romeo R, Manini M, Del Ninno E, Morabito A, Colombo M. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. *Hepatology* 2006; **43**: 1303-1310 [PMID: 16729298 DOI: 10.1002/hep.21176]

4   **Llovet JM**, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. *Hepatology* 1999; **30**: 1434-1440 [PMID: 10573522 DOI: 10.1002/hep.510300629]

5   **Fong Y**, Sun RL, Jarnagin W, Blumgart LH. An analysis of 412 cases of hepatocellular carcinoma at a Western center. *Ann Surg* 1999; **229**: 790-79; discussion 799-800 [PMID: 10363892]

6   **Llovet JM**, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. *Semin Liver Dis* 1999; **19**: 329-338 [PMID: 10518312 DOI: 10.1055/s-2007-1007122]

7   **Llovet JM**, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ. Design and endpoints of clinical trials in hepatocellular carcinoma. *J Natl Cancer Inst* 2008; **100**: 698-711 [PMID: 18477802 DOI: 10.1093/jnci/djn134]

8   **Cillo U**, Vitale A, Grigoletto F, Farinati F, Brolese A, Zanus G, Neri D, Boccagni P, Srsen N, D'Amico F, Ciarleglio FA, Bridda A, D'Amico DF. Prospective validation of the Barcelona Clinic Liver Cancer staging system. *J Hepatol* 2006; **44**: 723-731 [PMID: 16488051 DOI: 10.1016/j.jhep.2005.12.015]

9   **Cabibbo G**, Enea M, Attanasio M, Bruix J, Craxì A, Cammà C. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. *Hepatology* 2010; **51**: 1274-1283 [PMID: 20112254 DOI: 10.1002/hep.23485]

10   **Belghiti J**, Hiramatsu K, Benoist S, Massault P, Sauvanet A, Farges O. Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. *J Am Coll Surg* 2000; **191**: 38-46 [PMID: 10898182]

11   **Makuuchi M**, Sano K. The surgical approach to HCC: our progress and results in Japan. *Liver Transpl* 2004; **10**: S46-S52 [PMID: 14762839 DOI: 10.1002/lt.20044]

12   **Boyault S**, Rickman DS, de Reyniès A, Balabaud C, Rebouissou S, Jeannot E, Hérault A, Saric J, Belghiti J, Franco D, Bioulac-Sage P, Laurent-Puig P, Zucman-Rossi J. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. *Hepatology* 2007; **45**: 42-52 [PMID: 17187432 DOI: 10.1002/hep.21467]

13   **Hoshida Y**, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, Gupta S, Moore J, Wrobel MJ, Lerner J, Reich M, Chan JA, Glickman JN, Ikeda K, Hashimoto M, Watanabe G, Daidone MG, Roayaie S, Schwartz M, Thung S, Salvesen HB, Gabriel S, Mazzaferro V, Bruix J, Friedman SL, Kumada H, Llovet JM, Golub TR. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. *N Engl J Med* 2008; **359**: 1995-2004 [PMID: 18923165 DOI: 10.1056/NEJMoa0804525]

14   **Chiang DY**, Villanueva A, Hoshida Y, Peix J, Newell P, Min-

guez B, LeBlanc AC, Donovan DJ, Thung SN, Solé M, Tovar V, Alsinet C, Ramos AH, Barretina J, Roayaie S, Schwartz M, Waxman S, Bruix J, Mazzaferro V, Ligon AH, Najfeld V, Friedman SL, Sellers WR, Meyerson M, Llovet JM. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. *Cancer Res* 2008; **68**: 6779-6788 [PMID: 18701503 DOI: 10.1158/0008-5472.CAN-08-0742]

15   **Llovet JM**, Burroughs A, Bruix J. Hepatocellular carcinoma. *Lancet* 2003; **362**: 1907-1917 [PMID: 14667750 DOI: 10.1016/S0140-6736(03)14964-1]

16   **European Association For The Study Of The Liver**; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. *J Hepatol* 2012; **56**: 908-943 [PMID: 22424438 DOI: 10.1016/j.jhep.2011.12.001]

17   **Roayaie S**, Obeidat K, Sposito C, Mariani L, Bhoori S, Pellegrinelli A, Labow D, Llovet JM, Schwartz M, Mazzaferro V. Resection of hepatocellular cancer ≤2 cm: results from two Western centers. *Hepatology* 2013; **57**: 1426-1435 [PMID: 22576353 DOI: 10.1002/hep.25832]

18   **Mazzaferro V**, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. *N Engl J Med* 1996; **334**: 693-699 [PMID: 8594428 DOI: 10.1056/NEJM199603143341104]

19   **Yao FY**, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. *Hepatology* 2001; **33**: 1394-1403 [PMID: 11391528 DOI: 10.1053/jhep.2001.24563]

20   **Roayaie S**, Frischer JS, Emre SH, Fishbein TM, Sheiner PA, Sung M, Miller CM, Schwartz ME. Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. *Ann Surg* 2002; **235**: 533-539 [PMID: 11923610]

21   **Mazzaferro V**, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, Camerini T, Roayaie S, Schwartz ME, Grazi GL, Adam R, Neuhaus P, Salizzoni M, Bruix J, Forner A, De Carlis L, Cillo U, Burroughs AK, Troisi R, Rossi M, Gerunda GE, Lerut J, Belghiti J, Boin I, Gugenheim J, Rochling F, Van Hoek B, Majno P. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. *Lancet Oncol* 2009; **10**: 35-43 [PMID: 19058754 DOI: 10.1016/S1470-2045(08)70284-5]

22   **Sala M**, Llovet JM, Vilana R, Bianchi L, Solé M, Ayuso C, Brú C, Bruix J. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. *Hepatology* 2004; **40**: 1352-1360 [PMID: 15565564 DOI: 10.1002/hep.20465]

23   **Vivarelli M**, Guglielmi A, Ruzzenente A, Cucchetti A, Bellusci R, Cordiano C, Cavallari A. Surgical resection versus percutaneous radiofrequency ablation in the treatment of hepatocellular carcinoma on cirrhotic liver. *Ann Surg* 2004; **240**: 102-107 [PMID: 15213625]

24   **Chen MS**, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ, Lin XJ, Lau WY. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. *Ann Surg* 2006; **243**: 321-328 [PMID: 16495695 DOI: 10.1097/01.sla.0000201480.65519.b8]

25   A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. *N Engl J Med* 1995; **332**: 1256-1261 [PMID: 7708069 DOI: 10.1056/NEJM199505113321903]

26   **Llovet JM**, Real MI, Montaña X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, Rodés J, Bruix J. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. *Lancet* 2002; **359**: 1734-1739 [PMID: 12049862 DOI: 10.1016/S0140-6736(02)08649-X]

27   **Lo CM**, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, Wong J. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. *Hepatology* 2002; **35**: 1164-1171 [PMID: 11981766 DOI: 10.1053/jhep.2002.33156]

28   **Carr BI**. Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. *Liver Transpl* 2004; **10**: S107-S110 [PMID: 14762849 DOI: 10.1002/lt.20036]

29   **Salem R**, Lewandowski RJ, Kulik L, Wang E, Riaz A, Ryu RK, Sato KT, Gupta R, Nikolaidis P, Miller FH, Yaghmai V, Ibrahim SM, Senthilnathan S, Baker T, Gates VL, Atassi B, Newman S, Memon K, Chen R, Vogelzang RL, Nemcek AA, Resnick SA, Chrisman HB, Carr J, Omary RA, Abecassis M, Benson AB, Mulcahy MF. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. *Gastroenterology* 2011; **140**: 497-507.e2 [PMID: 21044630 DOI: 10.1053/j.gastro.2010.10.049]

30   **Llovet JM**, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J. Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med* 2008; **359**: 378-390 [PMID: 18650514 DOI: 10.1056/NEJMoa0708857]

31   **Cheng AL**, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. *Lancet Oncol* 2009; **10**: 25-34 [PMID: 19095497 DOI: 10.1016/S1470-2045(08)70285-7]

32   **Llovet JM**, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. *Semin Liver Dis* 2005; **25**: 181-200 [PMID: 15918147 DOI: 10.1055/s-2005-871198]

33   **Okamoto E**, Kyo A, Yamanaka N, Tanaka N, Kuwata K. Prediction of the safe limits of hepatectomy by combined volumetric and functional measurements in patients with impaired hepatic function. *Surgery* 1984; **95**: 586-592 [PMID: 6324403]

34   **Miyagawa S**, Makuuchi M, Kawasaki S, Kakazu T. Criteria for safe hepatic resection. *Am J Surg* 1995; **169**: 589-594 [PMID: 7771622]

35   **Bruix J**, Castells A, Bosch J, Feu F, Fuster J, Garcia-Pagan JC, Visa J, Bru C, Rodés J. Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. *Gastroenterology* 1996; **111**: 1018-1022 [PMID: 8831597]

36   **Cucchetti A**, Piscaglia F, Caturelli E, Benvegnù L, Vivarelli M, Ercolani G, Cescon M, Ravaioli M, Grazi GL, Bolondi L, Pinna AD. Comparison of recurrence of hepatocellular carcinoma after resection in patients with cirrhosis to its occurrence in a surveilled cirrhotic population. *Ann Surg Oncol* 2009; **16**: 413-422 [PMID: 19034578 DOI: 10.1245/s10434-008-0232-4]

37   **Ribero D**, Abdalla EK, Madoff DC, Donadon M, Loyer EM, Vauthey JN. Portal vein embolization before major hepatectomy and its effects on regeneration, resectability and outcome. *Br J Surg* 2007; **94**: 1386-1394 [PMID: 17583900 DOI: 10.1002/bjs.5836]

38   **Farges O**, Belghiti J, Kianmanesh R, Regimbeau JM, Santoro R, Vilgrain V, Denys A, Sauvanet A. Portal vein embolization before right hepatectomy: prospective clinical trial. *Ann Surg* 2003; **237**: 208-217 [PMID: 12560779 DOI: 10.1097/01.

SLA.0000048447.16651.7B]

39 **Arii S**, Tanaka S, Mitsunori Y, Nakamura N, Kudo A, Noguchi N, Irie T. Surgical strategies for hepatocellular carcinoma with special reference to anatomical hepatic resection and intraoperative contrast-enhanced ultrasonography. *Oncology* 2010; **78** Suppl 1: 125-130 [PMID: 20616594 DOI: 10.1159/000315240]

40 **Katz SC**, Shia J, Liau KH, Gonen M, Ruo L, Jarnagin WR, Fong Y, D'Angelica MI, Blumgart LH, Dematteo RP. Operative blood loss independently predicts recurrence and survival after resection of hepatocellular carcinoma. *Ann Surg* 2009; **249**: 617-623 [PMID: 19300227 DOI: 10.1097/SLA.0b013e31819ed22f]

41 **Roayaie S**, Blume IN, Thung SN, Guido M, Fiel MI, Hiotis S, Labow DM, Llovet JM, Schwartz ME. A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. *Gastroenterology* 2009; **137**: 850-855 [PMID: 19524573 DOI: 10.1053/j.gastro.2009.06.003]

42 **Imamura H**, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, Sugawara Y, Minagawa M, Takayama T, Kawasaki S, Makuuchi M. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. *J Hepatol* 2003; **38**: 200-207 [PMID: 12547409]

43 **Belghiti J**, Noun R, Malafosse R, Jagot P, Sauvanet A, Pierangeli F, Marty J, Farges O. Continuous versus intermittent portal triad clamping for liver resection: a controlled study. *Ann Surg* 1999; **229**: 369-375 [PMID: 10077049]

44 **Figueras J**, Llado L, Ruiz D, Ramos E, Busquets J, Rafecas A, Torras J, Fabregat J. Complete versus selective portal triad clamping for minor liver resections: a prospective randomized trial. *Ann Surg* 2005; **241**: 582-590 [PMID: 15798459]

45 **Gurusamy KS**, Pamecha V, Sharma D, Davidson BR. Techniques for liver parenchymal transection in liver resection. *Cochrane Database Syst Rev* 2009; **(1)**: CD006880 [PMID: 19160307 DOI: 10.1002/14651858.CD006880.pub2]

46 **Poon RT**, Fan ST, Lo CM, Liu CL, Wong J. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. *Ann Surg* 2002; **235**: 373-382 [PMID: 11882759]

47 **Wayne JD**, Lauwers GY, Ikai I, Doherty DA, Belghiti J, Yamaoka Y, Regimbeau JM, Nagorney DM, Do KA, Ellis LM, Curley SA, Pollock RE, Vauthey JN. Preoperative predictors of survival after resection of small hepatocellular carcinomas. *Ann Surg* 2002; **235**: 722-30; discussion 730-1 [PMID: 11981219]

48 **Shrager B**, Jibara G, Schwartz M, Roayaie S. Resection of hepatocellular carcinoma without cirrhosis. *Ann Surg* 2012; **255**: 1135-1143 [PMID: 22258064 DOI: 10.1097/SLA.0b013e31823e70a3]

49 **Sogawa H**, Shrager B, Jibara G, Tabrizian P, Roayaie S, Schwartz M. Resection or transplant-listing for solitary hepatitis C-associated hepatocellular carcinoma: an intention-to-treat analysis. *HPB* (Oxford) 2013; **15**: 134-141 [PMID: 23036070 DOI: 10.1111/j.1477-2574.2012.00548.x]

50 **Belghiti J**, Panis Y, Farges O, Benhamou JP, Fekete F. Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis. *Ann Surg* 1991; **214**: 114-117 [PMID: 1714267]

51 **Vauthey JN**, Lauwers GY, Esnaola NF, Do KA, Belghiti J, Mirza N, Curley SA, Ellis LM, Regimbeau JM, Rashid A, Cleary KR, Nagorney DM. Simplified staging for hepatocellular carcinoma. *J Clin Oncol* 2002; **20**: 1527-1536 [PMID: 11896101]

52 **Poon RT**, Fan ST. Evaluation of the new AJCC/UICC staging system for hepatocellular carcinoma after hepatic resection in Chinese patients. *Surg Oncol Clin N Am* 2003; **12**: 35-50, viii [PMID: 12735128]

53 **European Association For The Study Of The Liver**. EASL Clinical Practice Guidelines: management of chronic hepatitis B. *J Hepatol* 2009; **50**: 227-242 [PMID: 19054588 DOI: 10.1016/j.jhep.2008.10.001]

54 **Iloeje UH**, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. *Gastroenterology* 2006; **130**: 678-686 [PMID: 16530509 DOI: 10.1053/j.gastro.2005.11.016]

55 **Miyake Y**, Takaki A, Iwasaki Y, Yamamoto K. Meta-analysis: interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. *J Viral Hepat* 2010; **17**: 287-292 [PMID: 19732321 DOI: 10.1111/j.1365-2893.2009.01181.x]

56 **Shen YC**, Hsu C, Chen LT, Cheng CC, Hu FC, Cheng AL. Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): a meta-regression approach. *J Hepatol* 2010; **52**: 889-894 [PMID: 20395009 DOI: 10.1016/j.jhep.2009.12.041]

57 **Izumi R**, Shimizu K, Iyobe T, Ii T, Yagi M, Matsui O, Nonomura A, Miyazaki I. Postoperative adjuvant hepatic arterial infusion of Lipiodol containing anticancer drugs in patients with hepatocellular carcinoma. *Hepatology* 1994; **20**: 295-301 [PMID: 8045490]

58 **Lai EC**, Lo CM, Fan ST, Liu CL, Wong J. Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma: a randomized controlled trial. *Arch Surg* 1998; **133**: 183-188 [PMID: 9484732]

59 **Yamasaki S**, Hasegawa H, Kinoshita H, Furukawa M, Imaoka S, Takasaki K, Kakumoto Y, Saitsu H, Yamada R, Oosaki Y, Arii S, Okamoto E, Monden M, Ryu M, Kusano S, Kanematsu T, Ikeda K, Yamamoto M, Saoshiro T, Tsuzuki T. A prospective randomized trial of the preventive effect of pre-operative transcatheter arterial embolization against recurrence of hepatocellular carcinoma. *Jpn J Cancer Res* 1996; **87**: 206-211 [PMID: 8609071]

60 **Lau WY**, Lai EC, Leung TW, Yu SC. Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma: a prospective randomized trial-update on 5-year and 10-year survival. *Ann Surg* 2008; **247**: 43-48 [PMID: 18156922 DOI: 10.1097/SLA.0b013e3181571047]

61 **Lygidakis NJ**, Tsiliakos S. Multidisciplinary management of hepatocellular carcinoma. *Hepatogastroenterology* 1996; **43**: 1611-1619 [PMID: 8975975]

62 **Takayama T**, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y, Kakizoe T. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. *Lancet* 2000; **356**: 802-807 [PMID: 11022927 DOI: 10.1016/S0140-6736(00)02654-4]

63 **Yamamoto M**, Arii S, Sugahara K, Tobe T. Adjuvant oral chemotherapy to prevent recurrence after curative resection for hepatocellular carcinoma. *Br J Surg* 1996; **83**: 336-340 [PMID: 8665186]

64 **Kubo S**, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Yamazaki O, Shiomi S, Tamori A, Oka H, Igawa S, Kuroki T, Kinoshita H. Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. *Ann Intern Med* 2001; **134**: 963-967 [PMID: 11352697]

65 **Mazzaferro V**, Romito R, Schiavo M, Mariani L, Camerini T, Bhoori S, Capussotti L, Calise F, Pellicci R, Belli G, Tagger A, Colombo M, Bonino F, Majno P, Llovet JM. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. *Hepatology* 2006; **44**: 1543-1554 [PMID: 17133492 DOI: 10.1002/hep.21415]

66 **Lau WY**, Leung TW, Ho SK, Chan M, Machin D, Lau J, Chan AT, Yeo W, Mok TS, Yu SC, Leung NW, Johnson PJ. Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. *Lancet* 1999; **353**: 797-801 [PMID: 10459961]

67   **Boucher E**, Corbinais S, Rolland Y, Bourguet P, Guyader D, Boudjema K, Meunier B, Raoul JL. Adjuvant intra-arterial injection of iodine-131-labeled lipiodol after resection of hepatocellular carcinoma. *Hepatology* 2003; **38**: 1237-1241 [PMID: 14578862 DOI: 10.1053/jhep.2003.50473]

68   **Muto Y**, Moriwaki H, Ninomiya M, Adachi S, Saito A, Takasaki KT, Tanaka T, Tsurumi K, Okuno M, Tomita E, Nakamura T, Kojima T. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. *N Engl J Med* 1996; **334**: 1561-1567 [PMID: 8628336 DOI: 10.1056/NEJM199606133342402]

69   **Samuel M**, Chow PK, Chan Shih-Yen E, Machin D, Soo KC. Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma. *Cochrane Database Syst Rev* 2009; (**1**): CD001199 [PMID: 19160192 DOI: 10.1002/14651858. CD001199.pub2]

70   **Printz C**. Clinical trials of note. Sorafenib as adjuvant treatment in the prevention of disease recurrence in patients with hepatocellular carcinoma (HCC) (STORM). *Cancer* 2009; **115**: 4646 [PMID: 19806596 DOI: 10.1002/cncr.24673]

71   **Roayaie S**, Bassi D, Tarchi P, Labow D, Schwartz M. Second hepatic resection for recurrent hepatocellular cancer: a Western experience. *J Hepatol* 2011; **55**: 346-350 [PMID: 21147184 DOI: 10.1016/j.jhep.2010.11.026]

72   **Marín-Hargreaves G**, Azoulay D, Bismuth H. Hepatocellular carcinoma: surgical indications and results. *Crit Rev Oncol Hematol* 2003; **47**: 13-27 [PMID: 12853096]

73   **Majno PE**, Sarasin FP, Mentha G, Hadengue A. Primary liver resection and salvage transplantation or primary liver transplantation in patients with single, small hepatocellular carcinoma and preserved liver function: an outcome-oriented decision analysis. *Hepatology* 2000; **31**: 899-906 [PMID: 10733546 DOI: 10.1053/he.2000.5763]

74   **Belghiti J**, Cortes A, Abdalla EK, Régimbeau JM, Prakash K, Durand F, Sommacale D, Dondero F, Lesurtel M, Sauvanet A, Farges O, Kianmanesh R. Resection prior to liver transplantation for hepatocellular carcinoma. *Ann Surg* 2003; **238**: 885-92; discussion 892-3 [PMID: 14631225 DOI: 10.1097/01. sla.0000098621.74851.65]

75   **Adam R**, Azoulay D, Castaing D, Eshkenazy R, Pascal G, Hashizume K, Samuel D, Bismuth H. Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy? *Ann Surg* 2003; **238**: 508-18; discussion 518-9 [PMID: 14530722 DOI: 10.1097/01. sla.0000090449.87109.44]

76   **Cherqui D**, Laurent A, Mocellin N, Tayar C, Luciani A, Van Nhieu JT, Decaens T, Hurtova M, Memeo R, Mallat A, Duvoux C. Liver resection for transplantable hepatocellular carcinoma: long-term survival and role of secondary liver transplantation. *Ann Surg* 2009; **250**: 738-746 [PMID: 19801927 DOI: 10.1097/SLA.0b013e3181bd582b]

77   **Poon RT**, Fan ST, Lo CM, Liu CL, Wong J. Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. *Ann Surg* 1999; **229**: 216-222 [PMID: 10024103]

78   **Ho CM**, Lee PH, Shau WY, Ho MC, Wu YM, Hu RH. Survival in patients with recurrent hepatocellular carcinoma after primary hepatectomy: comparative effectiveness of treatment modalities. *Surgery* 2012; **151**: 700-709 [PMID: 22284764 DOI: 10.1016/j.surg.2011.12.015]

79   **Chen WT**, Chau GY, Lui WY, Tsay SH, King KL, Loong CC, Wu CW. Recurrent hepatocellular carcinoma after hepatic resection: prognostic factors and long-term outcome. *Eur J Surg Oncol* 2004; **30**: 414-420 [PMID: 15063895 DOI: 10.1016/ j.ejso.2004.01.013]

80   **Kishi Y**, Saiura A, Yamamoto J, Koga R, Seki M, Morimura R, Yoshioka R, Kokudo N, Yamaguchi T. Repeat treatment for recurrent hepatocellular carcinoma: is it validated? *Langenbecks Arch Surg* 2011; **396**: 1093-1100 [PMID: 21847622 DOI:

10.1007/s00423-011-0837-0]

81   **Lam CM**, Lo CM, Yuen WK, Liu CL, Fan ST. Prolonged survival in selected patients following surgical resection for pulmonary metastasis from hepatocellular carcinoma. *Br J Surg* 1998; **85**: 1198-1200 [PMID: 9752858 DOI: 10.1046/ j.1365-2168.1998.00846.x]

82   **Bismuth H**, Majno PE, Adam R. Liver transplantation for hepatocellular carcinoma. *Semin Liver Dis* 1999; **19**: 311-322 [PMID: 10518310 DOI: 10.1055/s-2007-1007120]

83   **Jonas S**, Bechstein WO, Steinmüller T, Herrmann M, Radke C, Berg T, Settmacher U, Neuhaus P. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. *Hepatology* 2001; **33**: 1080-1086 [PMID: 11343235 DOI: 10.1053/ jhep.2001.23561]

84   **Gondolesi GE**, Roayaie S, Muñoz L, Kim-Schluger L, Schiano T, Fishbein TM, Emre S, Miller CM, Schwartz ME. Adult living donor liver transplantation for patients with hepatocellular carcinoma: extending UNOS priority criteria. *Ann Surg* 2004; **239**: 142-149 [PMID: 14745320 DOI: 10.1097/01. sla.0000109022.32391.eb]

85   **Todo S**, Furukawa H; Japanese Study Group on Organ Transplantation. Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan. *Ann Surg* 2004; **240**: 451-49; discussion 459-61 [PMID: 15319716]

86   **Kwon CH**, Kim DJ, Han YS, Park JB, Choi GS, Kim SJ, Joh JW, Lee SK. HCC in living donor liver transplantation: can we expand the Milan criteria? *Dig Dis* 2007; **25**: 313-319 [PMID: 17960066 DOI: 10.1159/000106911]

87   **Lee SG**, Hwang S, Moon DB, Ahn CS, Kim KH, Sung KB, Ko GY, Park KM, Ha TY, Song GW. Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center. *Liver Transpl* 2008; **14**: 935-945 [PMID: 18581465 DOI: 10.1002/lt.21445]

88   **Herrero JI**, Sangro B, Quiroga J, Pardo F, Herraiz M, Cienfuegos JA, Prieto J. Influence of tumor characteristics on the outcome of liver transplantation among patients with liver cirrhosis and hepatocellular carcinoma. *Liver Transpl* 2001; **7**: 631-636 [PMID: 11460231 DOI: 10.1053/jlts.2001.25458]

89   **Jonas S**, Mittler J, Pascher A, Schumacher G, Theruvath T, Benckert C, Rudolph B, Neuhaus P. Living donor liver transplantation of the right lobe for hepatocellular carcinoma in cirrhosis in a European center. *Liver Transpl* 2007; **13**: 896-903 [PMID: 17538994 DOI: 10.1002/lt.21189]

90   **Toso C**, Trotter J, Wei A, Bigam DL, Shah S, Lancaster J, Grant DR, Greig PD, Shapiro AM, Kneteman NM. Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma. *Liver Transpl* 2008; **14**: 1107-1115 [PMID: 18668667 DOI: 10.1002/ lt.21484]

91   **Sugawara Y**, Tamura S, Makuuchi M. Living donor liver transplantation for hepatocellular carcinoma: Tokyo University series. *Dig Dis* 2007; **25**: 310-312 [PMID: 17960065 DOI: 10.1159/000106910]

92   **Volk ML**, Vijan S, Marrero JA. A novel model measuring the harm of transplanting hepatocellular carcinoma exceeding Milan criteria. *Am J Transplant* 2008; **8**: 839-846 [PMID: 18318783 DOI: 10.1111/j.1600-6143.2007.02138.x]

93   **Duffy JP**, Vardanian A, Benjamin E, Watson M, Farmer DG, Ghobrial RM, Lipshutz G, Yersiz H, Lu DS, Lassman C, Tong MJ, Hiatt JR, Busuttil RW. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. *Ann Surg* 2007; **246**: 502-509; discussion 509-511 [PMID: 17717454 DOI: 10.1097/ SLA.0b013e318148c704]

94   **Wiesner RH**, Freeman RB, Mulligan DC. Liver transplantation for hepatocellular cancer: the impact of the MELD allocation policy. *Gastroenterology* 2004; **127**: S261-S267 [PMID: 15508092]

95   **Martin AP**, Bartels M, Hauss J, Fangmann J. Overview of the MELD score and the UNOS adult liver allocation system. *Transplant Proc* 2007; **39**: 3169-3174 [PMID: 18089345 DOI: 10.1016/j.transproceed.2007.04.025]

96   **Vibert E**, Azoulay D, Hoti E, Iacopinelli S, Samuel D, Salloum C, Lemoine A, Bismuth H, Castaing D, Adam R. Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor. *Am J Transplant* 2010; **10**: 129-137 [PMID: 20070666 DOI: 10.1111/j.1600-6143.2009.02750.x]

97   **Majno P**, Giostra E, Mentha G. Management of hepatocellular carcinoma on the waiting list before liver transplantation: time for controlled trials? *Liver Transpl* 2007; **13**: S27-S35 [PMID: 17969086 DOI: 10.1002/lt.21328]

98   **Mazzaferro V**, Battiston C, Perrone S, Pulvirenti A, Regalia E, Romito R, Sarli D, Schiavo M, Garbagnati F, Marchianò A, Spreafico C, Camerini T, Mariani L, Miceli R, Andreola S. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. *Ann Surg* 2004; **240**: 900-909 [PMID: 15492574]

99   **Graziadei IW**, Sandmueller H, Waldenberger P, Koenigsrainer A, Nachbaur K, Jaschke W, Margreiter R, Vogel W. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. *Liver Transpl* 2003; **9**: 557-563 [PMID: 12783395 DOI: 10.1053/jlts.2003.50106]

100   **Yao FY**, Kerlan RK, Hirose R, Davern TJ, Bass NM, Feng S, Peters M, Terrault N, Freise CE, Ascher NL, Roberts JP. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. *Hepatology* 2008; **48**: 819-827 [PMID: 18688876 DOI: 10.1002/hep.22412]

101   **Ravaioli M**, Grazi GL, Piscaglia F, Trevisani F, Cescon M, Ercolani G, Vivarelli M, Golfieri R, D'Errico Grigioni A, Panzini I, Morelli C, Bernardi M, Bolondi L, Pinna AD. Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria. *Am J Transplant* 2008; **8**: 2547-2557 [PMID: 19032223 DOI: 10.1111/j.1600-6143.2008.02409.x]

102   **Bhoori S**, Sposito C, Germini A, Coppa J, Mazzaferro V. The challenges of liver transplantation for hepatocellular carcinoma on cirrhosis. *Transpl Int* 2010; **23**: 712-722 [PMID: 20492616 DOI: 10.1111/j.1432-2277.2010.01111.x]

103   **Clavien PA**, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. *Lancet Oncol* 2012; **13**: e11-e22 [PMID: 22047762 DOI: 10.1016/S1470-2045(11)70175-9]

104   **Lo CM**, Fan ST, Liu CL, Chan SC, Ng IO, Wong J. Living donor versus deceased donor liver transplantation for early irresectable hepatocellular carcinoma. *Br J Surg* 2007; **94**: 78-86 [PMID: 17016793 DOI: 10.1002/bjs.5528]

105   **Fisher RA**, Kulik LM, Freise CE, Lok AS, Shearon TH, Brown RS, Ghobrial RM, Fair JH, Olthoff KM, Kam I, Berg CL. Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation. *Am J Transplant* 2007; **7**: 1601-1608 [PMID: 17511683 DOI: 10.1111/j.1600-6143.2007.01802.x]

106   **Prasad KR**, Young RS, Burra P, Zheng SS, Mazzaferro V, Moon DB, Freeman RB. Summary of candidate selection and expanded criteria for liver transplantation for hepatocellular carcinoma: a review and consensus statement. *Liver Transpl* 2011; **17** Suppl 2: S81-S89 [PMID: 21748847 DOI: 10.1002/lt.22380]

107   **Majno P**, Mazzaferro V. Living donor liver transplantation for hepatocellular carcinoma exceeding conventional criteria: questions, answers and demands for a common language. *Liver Transpl* 2006; **12**: 896-898 [PMID: 16721768 DOI: 10.1002/lt.20808]

108   **Iwatsuki S**, Starzl TE, Sheahan DG, Yokoyama I, Demetris AJ, Todo S, Tzakis AG, Van Thiel DH, Carr B, Selby R. Hepatic resection versus transplantation for hepatocellular carcinoma. *Ann Surg* 1991; **214**: 221-28; discussion 228-9 [PMID: 1656903]

109   **Bismuth H**, Chiche L, Adam R, Castaing D, Diamond T, Dennison A. Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. *Ann Surg* 1993; **218**: 145-151 [PMID: 8393649]

110   **Roayaie S**, Haim MB, Emre S, Fishbein TM, Sheiner PA, Miller CM, Schwartz ME. Comparison of surgical outcomes for hepatocellular carcinoma in patients with hepatitis B versus hepatitis C: a western experience. *Ann Surg Oncol* 2000; **7**: 764-770 [PMID: 11129425]

111   **Hemming AW**, Nelson DR, Reed AI. Liver transplantation for hepatocellular carcinoma. *Minerva Chir* 2002; **57**: 575-585 [PMID: 12370659]

112   **D'Amico F**, Schwartz M, Vitale A, Tabrizian P, Roayaie S, Thung S, Guido M, del Rio Martin J, Schiano T, Cillo U. Predicting recurrence after liver transplantation in patients with hepatocellular carcinoma exceeding the up-to-seven criteria. *Liver Transpl* 2009; **15**: 1278-1287 [PMID: 19790142 DOI: 10.1002/lt.21842]

113   **Bozorgzadeh A**, Orloff M, Abt P, Tsoulfas G, Younan D, Kashyap R, Jain A, Mantry P, Maliakkal B, Khorana A, Schwartz S. Survival outcomes in liver transplantation for hepatocellular carcinoma, comparing impact of hepatitis C versus other etiology of cirrhosis. *Liver Transpl* 2007; **13**: 807-813 [PMID: 17539001 DOI: 10.1002/lt.21054]

114   **Bruix J**, Sherman M. Management of hepatocellular carcinoma. *Hepatology* 2005; **42**: 1208-1236 [PMID: 16250051 DOI: 10.1002/hep.20933]

115   **Roayaie S**, Schwartz JD, Sung MW, Emre SH, Miller CM, Gondolesi GE, Krieger NR, Schwartz ME. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. *Liver Transpl* 2004; **10**: 534-540 [PMID: 15048797 DOI: 10.1002/lt.20128]

116   **Schwartz M**, Roayaie S, Llovet J. How should patients with hepatocellular carcinoma recurrence after liver transplantation be treated? *J Hepatol* 2005; **43**: 584-589 [PMID: 16120468 DOI: 10.1016/j.jhep.2005.07.019]

117   **Taketomi A**, Fukuhara T, Morita K, Kayashima H, Ninomiya M, Yamashita Y, Ikegami T, Uchiyama H, Yoshizumi T, Soejima Y, Shirabe K, Maehara Y. Improved results of a surgical resection for the recurrence of hepatocellular carcinoma after living donor liver transplantation. *Ann Surg Oncol* 2010; **17**: 2283-2289 [PMID: 20204531 DOI: 10.1245/s10434-010-0999-y]

118   **Zhou B**, Shan H, Zhu KS, Jiang ZB, Guan SH, Meng XC, Zeng XC. Chemoembolization with lobaplatin mixed with iodized oil for unresectable recurrent hepatocellular carcinoma after orthotopic liver transplantation. *J Vasc Interv Radiol* 2010; **21**: 333-338 [PMID: 20116286 DOI: 10.1016/j.jvir.2009.11.006]

119   **Kita Y**, Klintmalm G, Kobayashi S, Yanaga K. Retransplantation for de novo hepatocellular carcinoma in a liver allograft with recurrent hepatitis B cirrhosis 14 years after primary liver transplantation. *Dig Dis Sci* 2007; **52**: 3392-3393 [PMID: 17404871 DOI: 10.1007/s10620-006-9574-6]

120   **Chen GH**, Fu BS, Yang Y, Cai CJ, Lu MQ, Li H, Wang GS, Yi SH, Xu C, Zhang JF, Zhang T, Wang GY. Early liver retransplantation versus late liver retransplantation: analysis of a single-center experience. *Chin Med J* (Engl) 2008; **121**: 1992-1996 [PMID: 19080262]

121   **Lencioni R**. Loco-regional treatment of hepatocellular carcinoma. *Hepatology* 2010; **52**: 762-773 [PMID: 20564355 DOI: 10.1002/hep.23725]

122   **Shiina S**, Teratani T, Obi S, Sato S, Tateishi R, Fujishima T, Ishikawa T, Koike Y, Yoshida H, Kawabe T, Omata M. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. *Gastro-*

enterology 2005; **129**: 122-130 [PMID: 16012942]

123 **Lencioni R**, Crocetti L. A critical appraisal of the literature on local ablative therapies for hepatocellular carcinoma. *Clin Liver Dis* 2005; **9**: 301-14, viii [PMID: 15831275 DOI: 10.1016/j.cld.2004.12.002]

124 **Rhim H**. Complications of radiofrequency ablation in hepatocellular carcinoma. *Abdom Imaging* 2005; **30**: 409-418 [PMID: 15688113 DOI: 10.1007/s00261-004-0255-7]

125 **Lencioni R**, Crocetti L. Image-guided thermal ablation of hepatocellular carcinoma. *Crit Rev Oncol Hematol* 2008; **66**: 200-207 [PMID: 18304832 DOI: 10.1016/j.critrevonc.2008.01.003]

126 **Llovet JM**, Vilana R, Brú C, Bianchi L, Salmeron JM, Boix L, Ganau S, Sala M, Pagès M, Ayuso C, Solé M, Rodés J, Bruix J. Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. *Hepatology* 2001; **33**: 1124-1129 [PMID: 11343240 DOI: 10.1053/jhep.2001.24233]

127 **Lu DS**, Yu NC, Raman SS, Limanond P, Lassman C, Murray K, Tong MJ, Amado RG, Busuttil RW. Radiofrequency ablation of hepatocellular carcinoma: treatment success as defined by histologic examination of the explanted liver. *Radiology* 2005; **234**: 954-960 [PMID: 15681691 DOI: 10.1148/radiol.2343040153]

128 **Lencioni RA**, Allgaier HP, Cioni D, Olschewski M, Deibert P, Crocetti L, Frings H, Laubenberger J, Zuber I, Blum HE, Bartolozzi C. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. *Radiology* 2003; **228**: 235-240 [PMID: 12759473 DOI: 10.1148/radiol.2281020718]

129 **Lin SM**, Lin CJ, Lin CC, Hsu CW, Chen YC. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma & lt; or =4 cm. *Gastroenterology* 2004; **127**: 1714-1723 [PMID: 15578509]

130 **Lin SM**, Lin CJ, Lin CC, Hsu CW, Chen YC. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. *Gut* 2005; **54**: 1151-1156 [PMID: 16009687 DOI: 10.1136/gut.2004.045203]

131 **Brunello F**, Veltri A, Carucci P, Pagano E, Ciccone G, Moretto P, Sacchetto P, Gandini G, Rizzetto M. Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: A randomized controlled trial. *Scand J Gastroenterol* 2008; **43**: 727-735 [PMID: 18569991 DOI: 10.1080/00365520701885481]

132 **Lencioni R**, Cioni D, Crocetti L, Franchini C, Pina CD, Lera J, Bartolozzi C. Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. *Radiology* 2005; **234**: 961-967 [PMID: 15665226 DOI: 10.1148/radiol.2343040350]

133 **Huang J**, Yan L, Cheng Z, Wu H, Du L, Wang J, Xu Y, Zeng Y. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. *Ann Surg* 2010; **252**: 903-912 [PMID: 21107100 DOI: 10.1097/SLA.0b013e3181efc656]

134 **Hasegawa K**, Kokudo N, Makuuchi M, Izumi N, Ichida T, Kudo M, Ku Y, Sakamoto M, Nakashima O, Matsui O, Matsuyama Y. Comparison of resection and ablation for hepatocellular carcinoma: a cohort study based on a Japanese nationwide survey. *J Hepatol* 2013; **58**: 724-729 [PMID: 23178708 DOI: 10.1016/j.jhep.2012.11.009]

135 **Livraghi T**, Meloni F, Di Stasi M, Rolle E, Solbiati L, Tinelli C, Rossi S. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? *Hepatology* 2008; **47**: 82-89 [PMID: 18008357 DOI: 10.1002/hep.21933]

136 **Shibata T**, Iimuro Y, Yamamoto Y, Maetani Y, Ametani F, Itoh K, Konishi J. Small hepatocellular carcinoma: comparison of radio-frequency ablation and percutaneous microwave coagulation therapy. *Radiology* 2002; **223**: 331-337 [PMID: 11997534 DOI: 10.1148/radiol.2232010775]

137 **Oliveri RS**, Wetterslev J, Gluud C. Transarterial (chemo) embolisation for unresectable hepatocellular carcinoma. *Cochrane Database Syst Rev* 2011; (**3**): CD004787 [PMID: 21412886 DOI: 10.1002/14651858.CD004787.pub2]

138 **Molinari M**, Kachura JR, Dixon E, Rajan DK, Hayeems EB, Asch MR, Benjamin MS, Sherman M, Gallinger S, Burnett B, Feld R, Chen E, Greig PD, Grant DR, Knox JJ. Transarterial chemoembolisation for advanced hepatocellular carcinoma: results from a North American cancer centre. *Clin Oncol* (R Coll Radiol) 2006; **18**: 684-692 [PMID: 17100154]

139 **Lladó L**, Virgili J, Figueras J, Valls C, Dominguez J, Rafecas A, Torras J, Fabregat J, Guardiola J, Jaurrieta E. A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization. *Cancer* 2000; **88**: 50-57 [PMID: 10618605]

140 **Lammer J**, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, Pitton M, Sergent G, Pfammatter T, Terraz S, Benhamou Y, Avajon Y, Gruenberger T, Pomoni M, Langenberger H, Schuchmann M, Dumortier J, Mueller C, Chevallier P, Lencioni R. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. *Cardiovasc Intervent Radiol* 2010; **33**: 41-52 [PMID: 19908093 DOI: 10.1007/s00270-009-9711-7]

141 **Lin DY**, Liaw YF, Lee TY, Lai CM. Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma--a randomized controlled trial. *Gastroenterology* 1988; **94**: 453-456 [PMID: 2826285]

142 **Pelletier G**, Roche A, Ink O, Anciaux ML, Derhy S, Rougier P, Lenoir C, Attali P, Etienne JP. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. *J Hepatol* 1990; **11**: 181-184 [PMID: 2174933]

143 **Bruix J**, Llovet JM, Castells A, Montañá X, Brú C, Ayuso MC, Vilana R, Rodés J. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. *Hepatology* 1998; **27**: 1578-1583 [PMID: 9620330 DOI: 10.1002/hep.510270617]

144 **Nicolini A**, Martinetti L, Crespi S, Maggioni M, Sangiovanni A. Transarterial chemoembolization with epirubicin-eluting beads versus transarterial embolization before liver transplantation for hepatocellular carcinoma. *J Vasc Interv Radiol* 2010; **21**: 327-332 [PMID: 20097098 DOI: 10.1016/j.jvir.2009.10.038]

145 **Kwon JH**, Bae SH, Kim JY, Choi BO, Jang HS, Jang JW, Choi JY, Yoon SK, Chung KW. Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer. *BMC Cancer* 2010; **10**: 475 [PMID: 20813065 DOI: 10.1186/1471-2407-10-475]

146 **Andolino DL**, Johnson CS, Maluccio M, Kwo P, Tector AJ, Zook J, Johnstone PA, Cardenes HR. Stereotactic body radiotherapy for primary hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys* 2011; **81**: e447-e453 [PMID: 21645977 DOI: 10.1016/j.ijrobp.2011.04.011]

147 **Huang WY**, Jen YM, Lee MS, Chang LP, Chen CM, Ko KH, Lin KT, Lin JC, Chao HL, Lin CS, Su YF, Fan CY, Chang YW. Stereotactic body radiation therapy in recurrent hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys* 2012; **84**: 355-361 [PMID: 22342300 DOI: 10.1016/j.ijrobp.2011.11.058]

148 **Kang JK**, Kim MS, Cho CK, Yang KM, Yoo HJ, Kim JH, Bae SH, Jung da H, Kim KB, Lee DH, Han CJ, Kim J, Park SC, Kim YH. Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization. *Cancer* 2012; **118**: 5424-5431 [PMID: 22570179 DOI: 10.1002/cncr.27533]

149   **Facciuto ME**, Singh MK, Rochon C, Sharma J, Gimenez C, Katta U, Moorthy CR, Bentley-Hibbert S, Rodriguez-Davalos M, Wolf DC. Stereotactic body radiation therapy in hepatocellular carcinoma and cirrhosis: evaluation of radiological and pathological response. *J Surg Oncol* 2012; **105**: 692-698 [PMID: 21960321 DOI: 10.1002/jso.22104]

150   **Sangro B**, Bilbao JI, Boan J, Martinez-Cuesta A, Benito A, Rodriguez J, Panizo A, Gil B, Inarrairaegui M, Herrero I, Quiroga J, Prieto J. Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys* 2006; **66**: 792-800 [PMID: 16904840 DOI: 10.1016/j.ijrobp.2006.05.065]

151   **Kulik LM**, Carr BI, Mulcahy MF, Lewandowski RJ, Atassi B, Ryu RK, Sato KT, Benson A, Nemcek AA, Gates VL, Abecassis M, Omary RA, Salem R. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. *Hepatology* 2008; **47**: 71-81 [PMID: 18027884 DOI: 10.1002/hep.21980]

152   **Hilgard P**, Hamami M, Fouly AE, Scherag A, Müller S, Ertle J, Heusner T, Cicinnati VR, Paul A, Bockisch A, Gerken G, Antoch G. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. *Hepatology* 2010; **52**: 1741-1749 [PMID: 21038413 DOI: 10.1002/hep.23944]

153   **Salem R**, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, Atassi B, Baker T, Gates V, Miller FH, Sato KT, Wang E, Gupta R, Benson AB, Newman SB, Omary RA, Abecassis M, Kulik L. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. *Gastroenterology* 2010; **138**: 52-64 [PMID: 19766639 DOI: 10.1053/j.gastro.2009.09.006]

154   **Abou-Alfa GK**. Selection of patients with hepatocellular carcinoma for sorafenib. *J Natl Compr Canc Netw* 2009; **7**: 397-403 [PMID: 19406040]

155   **Abou-Alfa GK**, Amadori D, Santoro A, Figer A, De Greve J, Lathia C, Voliotis D, Anderson S, Moscovici M, Ricci S. Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B Cirrhosis. *Gastrointest Cancer Res* 2011; **4**: 40-44 [PMID: 21673874]

156   **Hollebecque A**, Cattan S, Romano O, Sergent G, Mourad A, Louvet A, Dharancy S, Boleslawski E, Truant S, Pruvot FR, Hebbar M, Ernst O, Mathurin P. Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score. *Aliment Pharmacol Ther* 2011; **34**: 1193-1201 [PMID: 21958438 DOI: 10.1111/j.1365-2036.2011.04860.x]

157   **Kim JE**, Ryoo BY, Ryu MH, Chang HM, Suh DJ, Lee HC, Lim YS, Kim KM, Kang YK. Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function. *Cancer Chemother Pharmacol* 2011; **68**: 1285-1290 [PMID: 21445543 DOI: 10.1007/s00280-011-1616-x]

158   **Toh HC**, Chen PJ, Carr BI, Knox JJ, Gill S, Ansell P, McKeegan EM, Dowell B, Pedersen M, Qin Q, Qian J, Scappaticci FA, Ricker JL, Carlson DM, Yong WP. Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma. *Cancer* 2013; **119**: 380-387 [PMID: 22833179 DOI: 10.1002/cncr.27758]

159   **Hsu CH**, Shen YC, Lin ZZ, Chen PJ, Shao YY, Ding YH, Hsu C, Cheng AL. Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. *J Hepatol* 2010; **53**: 126-131 [PMID: 20416968 DOI: 10.1016/j.jhep.2010.01.035]

160   **Thomas MB**, Chadha R, Glover K, Wang X, Morris J, Brown T, Rashid A, Dancey J, Abbruzzese JL. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. *Cancer* 2007; **110**: 1059-1067 [PMID: 17623837 DOI: 10.1002/cncr.22886]

161   **Thomas MB**, Morris JS, Chadha R, Iwasaki M, Kaur H, Lin E, Kaseb A, Glover K, Davila M, Abbruzzese J. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. *J Clin Oncol* 2009; **27**: 843-850 [PMID: 19139433 DOI: 10.1200/JCO.2008.18.3301]

162   **Faivre S**, Raymond E, Boucher E, Douillard J, Lim HY, Kim JS, Zappa M, Lanzalone S, Lin X, Deprimo S, Harmon C, Ruiz-Garcia A, Lechuga MJ, Cheng AL. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. *Lancet Oncol* 2009; **10**: 794-800 [PMID: 19586800 DOI: 10.1016/S1470-2045(09)70171-8]

163   **Villanueva A**, Llovet JM. Targeted therapies for hepatocellular carcinoma. *Gastroenterology* 2011; **140**: 1410-1426 [PMID: 21406195 DOI: 10.1053/j.gastro.2011.03.006]

Baishideng®